Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.75  1.15  29.49%   
About 62% of Lisata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
over a month ago at gurufocus.com         
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
over a month ago at businesswire.com         
Shareholder Alert Ademi LLP investigates whether Arcadia Biosciences, Inc. is obtaining a Fair Price...
businesswire News
over a month ago at gurufocus.com         
Shareholder Alert Ademi LLP investigates whether Arcadia Biosciences, Inc. ...
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong...
Yahoo News
over a month ago at businesswire.com         
Vevo Therapeutics se asocia con Parse Biosciences GigaLab para generar un atlas de 100 millones de c...
businesswire News
over a month ago at businesswire.com         
Riassunto Vevo Therapeutics stringe una partnership con Parse Biosciences GigaLab volta a creare un ...
businesswire News
over a month ago at gurufocus.com         
RKDA Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Arcadia Biosciences, ...
Gurufocus Stories at Macroaxis
over a month ago at investing.com         
Castle Biosciences director Daniel Bradbury sells 243,692 in stock
Investing News at Macroaxis
over a month ago at investing.com         
BMO sets 21 target for IGM Biosciences with Outperform rating
Investing News at Macroaxis
over a month ago at businesswire.com         
Vevo Therapeutics sassocie au GigaLab de Parse Biosciences pour gnrer un atlas cellulaire de 100 mil...
businesswire News
over a month ago at businesswire.com         
Vevo Therapeutics faz parceria com a Parse Biosciences GigaLab para gerar um atlas de 100 milhes de ...
businesswire News
over a month ago at businesswire.com         
Slingshot Biosciences Welcomes Visionary Leader and Industry Expert Dr. Nimisha Srivastava as New Ch...
businesswire News
over a month ago at gurufocus.com         
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on ...
Gurufocus Stories at Macroaxis
over a month ago at gurufocus.com         
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch ...
Gurufocus Stories at Macroaxis
over a month ago at investing.com         
Solid Biosciences COO David Howton sells 28,396 in stock
Investing News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
CEOs Directory
Screen CEOs from public companies around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments